Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKLINASDAQ:DRIONYSE:NSPRNASDAQ:RCLF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKLIAkili$0.43$0.43$0.19▼$1.25$34.01M1.722.20 million shsN/ADRIODarioHealth$0.67-2.2%$0.71$0.50▼$1.55$29.79M1.58286,285 shs93,280 shsNSPRInspireMD$2.29+1.3%$2.47$1.99▼$3.80$70.15M0.5965,062 shs167,861 shsRCLFRosecliff Acquisition Corp I$11.06$8.96▼$19.50$78.49M0.0264,402 shs150,200 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKLIAkili0.00%0.00%0.00%0.00%-0.62%DRIODarioHealth0.00%-2.90%-6.69%+9.44%-43.70%NSPRInspireMD0.00%-6.91%-9.49%-14.87%-8.23%RCLFRosecliff Acquisition Corp I0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKLIAkiliN/AN/AN/AN/AN/AN/AN/AN/ADRIODarioHealth1.8721 of 5 stars3.30.00.00.02.60.81.3NSPRInspireMD3.1559 of 5 stars3.54.00.00.02.02.50.6RCLFRosecliff Acquisition Corp IN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKLIAkili 0.00N/AN/AN/ADRIODarioHealth 2.67Moderate Buy$2.00198.51% UpsideNSPRInspireMD 3.00Buy$4.5096.51% UpsideRCLFRosecliff Acquisition Corp I 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DRIO, AKLI, NSPR, and RCLF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025DRIODarioHealthLitchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.005/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKLIAkili$1.95M17.46N/AN/A$0.75 per share0.58DRIODarioHealth$27.04M1.10N/AN/A$2.11 per share0.32NSPRInspireMD$7.03M9.98N/AN/A$1.83 per share1.25RCLFRosecliff Acquisition Corp IN/AN/AN/A8.27($2.13) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKLIAkili-$59.49M-$0.61N/AN/AN/A-2,492.04%-79.93%-59.16%N/ADRIODarioHealth-$42.75M-$0.56N/AN/AN/A-159.80%-65.81%-38.41%8/6/2025 (Estimated)NSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/ARCLFRosecliff Acquisition Corp I$11.04MN/A0.00N/AN/AN/A-1.62%0.31%N/ALatest DRIO, AKLI, NSPR, and RCLF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DRIODarioHealth-$0.07-$0.14-$0.07-$0.14$7.48 million$6.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKLIAkiliN/AN/AN/AN/AN/ADRIODarioHealthN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ARCLFRosecliff Acquisition Corp IN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKLIAkili0.085.805.80DRIODarioHealth0.262.011.77NSPRInspireMDN/A6.396.05RCLFRosecliff Acquisition Corp IN/A0.110.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKLIAkili53.12%DRIODarioHealth33.39%NSPRInspireMD44.78%RCLFRosecliff Acquisition Corp I3.23%Insider OwnershipCompanyInsider OwnershipAKLIAkili10.10%DRIODarioHealth11.20%NSPRInspireMD29.72%RCLFRosecliff Acquisition Corp I0.41%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKLIAkili13078.73 million70.78 millionOptionableDRIODarioHealth20044.46 million39.48 millionOptionableNSPRInspireMD5030.64 million18.33 millionOptionableRCLFRosecliff Acquisition Corp I36.78 million6.76 millionNot OptionableDRIO, AKLI, NSPR, and RCLF HeadlinesRecent News About These CompaniesVertex Technology Acquisition Corporation Ltd. (VT1.SI)December 8, 2023 | sg.finance.yahoo.comDistoken Acquisition Corporation (NASDAQ:DIST) is largely controlled by institutional shareholders who own 59% of the companyNovember 7, 2023 | finance.yahoo.comSPAC Rosecliff shareholders approve merger with Spectral MDSeptember 8, 2023 | msn.comPre-market Movers: GROM, DMS, RCLF, PLTN, SPRB…September 8, 2023 | markets.businessinsider.comWhy Is Rosecliff Acquisition (RCLF) Stock Down 17% Today?September 8, 2023 | msn.comRosecliff Acquisition Corp I (NASDAQ: RCLF)August 19, 2023 | fool.comFiling of Updated Form S-4 by Rosecliff & Updated Investor PresentationAugust 15, 2023 | pharmiweb.comPDefinitive Proxy Statement and Prospectus Mailed by Rosecliff Acquisition Corporation IAugust 15, 2023 | pharmiweb.comPUpdated Investor Presentation & Filing by Rosecliff Acquisition Corp. IAugust 1, 2023 | pharmiweb.comPRosecliff Acquisition Corp I Class AJuly 15, 2023 | morningstar.comMSpectral MD Holdings, Ltd ("Spectral MD" or the "Company") Announces Publication of Peer Reviewed Proof-of-Concept Study Evaluating DeepView® Technology in Journal of Burn Care & ResearchJune 13, 2023 | finance.yahoo.comSpectral MD Announces Podium Presentation at 2023 American Burn Association Annual ConferenceMay 18, 2023 | finance.yahoo.comSpectral MD Holdings, Ltd. $4.0 Million Grant Award from the Medical Technology Enterprise ConsortiumApril 18, 2023 | finance.yahoo.comSpectral MD to list on Nasdaq via SPAC merger with RosecliffApril 11, 2023 | msn.comSpectral MD Holdings, Ltd., an FDA Breakthrough Designated company focused on Artificial Intelligence driven Medical Diagnostic Solutions, to be Listed on Nasdaq Through Business Combination with Rosecliff Acquisition Corp IApril 11, 2023 | finance.yahoo.comRosecliff Acquisition Corp. I Cl AJanuary 21, 2023 | wsj.comTastemaker Acquisition Corp. (NASDAQ:TMKR) is largely controlled by institutional shareholders who own 68% of the companyOctober 14, 2022 | yahoo.comRosecliff Acquisition Stock (NASDAQ:RCLFU), Analyst Ratings, Price Targets, PredictionsOctober 9, 2022 | benzinga.comRosecliff Acquisition Corp I (RCLFW)September 13, 2022 | finance.yahoo.comRosecliff Acquisition Corp I (RCLF)July 2, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRIO, AKLI, NSPR, and RCLF Company DescriptionsAkili NASDAQ:AKLIAkili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.DarioHealth NASDAQ:DRIO$0.67 -0.02 (-2.20%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.67 0.00 (0.00%) As of 06/27/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.InspireMD NYSE:NSPR$2.29 +0.03 (+1.33%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.15 -0.14 (-6.29%) As of 05:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Rosecliff Acquisition Corp I NASDAQ:RCLFRosecliff Acquisition Corp I does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Rosecliff Acquisition Corp I was incorporated in 2020 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
